Acadia Pharmaceuticals (ACAD) Net Margin (2010 - 2026)

Acadia Pharmaceuticals' Net Margin history runs 17 years deep, the most recent figure standing at 1.36% for Q1 2026.

• In Q1 2026, Net Margin fell 641.0% year-over-year to 1.36%; the TTM figure through Mar 2026 stood at 34.3% (up 1132.0% YoY), while the FY2025 annual figure was 36.49%, up 1285.0% from the prior year.
• Net Margin was 1.36% for Q1 2026 at Acadia Pharmaceuticals, down from 96.33% in the prior quarter.
• In the past five years, Net Margin ranged from a high of 96.33% in Q4 2025 to a low of 97.91% in Q1 2022.
• Historically, Net Margin has averaged 0.62% across 5 years, with a median of 7.77% in 2025.
• The sharpest annual moves came in 2022 and 2023: Net Margin plunged 3555 bps in 2022, then jumped 6159 bps in 2023.
• A 5-year view of Net Margin shows it stood at 30.53% in 2022, then surged by 165 bps to 19.82% in 2023, then soared by 179 bps to 55.37% in 2024, then soared by 74 bps to 96.33% in 2025, then plunged by 99 bps to 1.36% in 2026.
• The last three Net Margin figures came in at 1.36% (Q1 2026), 96.33% (Q4 2025), and 25.76% (Q3 2025), per Business Quant data.